Widmer N - Search Results

1

Therapeutic drug monitoring of targeted anticancer therapy.

Decosterd LA, Widmer N, Zaman K, Cardoso E, Buclin T, Csajka C. Decosterd LA, et al. Among authors: widmer n. Biomark Med. 2015;9(9):887-93. doi: 10.2217/bmm.15.78. Epub 2015 Sep 3. Biomark Med. 2015. PMID: 26333311 Review.

2

Functional consequence of MDR1 expression on imatinib intracellular concentrations.

Widmer N, Colombo S, Buclin T, Decosterd LA. Widmer N, et al. Blood. 2003 Aug 1;102(3):1142. doi: 10.1182/blood-2003-03-0993. Blood. 2003. PMID: 12869489 Free article. No abstract available.

3

Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection.

Widmer N, Béguin A, Rochat B, Buclin T, Kovacsovics T, Duchosal MA, Leyvraz S, Rosselet A, Biollaz J, Decosterd LA. Widmer N, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Apr 25;803(2):285-92. doi: 10.1016/j.jchromb.2004.01.006. J Chromatogr B Analyt Technol Biomed Life Sci. 2004. PMID: 15063337

4

Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term.

Neef M, Ledermann M, Saegesser H, Schneider V, Widmer N, Decosterd LA, Rochat B, Reichen J. Neef M, et al. Among authors: widmer n. J Hepatol. 2006 Jan;44(1):167-75. doi: 10.1016/j.jhep.2005.06.015. Epub 2005 Jul 12. J Hepatol. 2006. PMID: 16168515

5

Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia.

Gambillara E, Laffitte E, Widmer N, Decosterd LA, Duchosal MA, Kovacsovics T, Panizzon RG. Gambillara E, et al. Among authors: widmer n. Dermatology. 2005;211(4):363-5. doi: 10.1159/000088510. Dermatology. 2005. PMID: 16286749

6

Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.

Widmer N, Decosterd LA, Csajka C, Leyvraz S, Duchosal MA, Rosselet A, Rochat B, Eap CB, Henry H, Biollaz J, Buclin T. Widmer N, et al. Br J Clin Pharmacol. 2006 Jul;62(1):97-112. doi: 10.1111/j.1365-2125.2006.02719.x. Br J Clin Pharmacol. 2006. PMID: 16842382 Free PMC article.

7

Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels.

Widmer N, Rumpold H, Untergasser G, Fayet A, Buclin T, Decosterd LA. Widmer N, et al. Leukemia. 2007 Jul;21(7):1561-2; author reply 1562-4. doi: 10.1038/sj.leu.2404671. Epub 2007 Apr 12. Leukemia. 2007. PMID: 17429432 No abstract available.

8

Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry.

Rochat B, Fayet A, Widmer N, Lahrichi SL, Pesse B, Décosterd LA, Biollaz J. Rochat B, et al. Among authors: widmer n. J Mass Spectrom. 2008 Jun;43(6):736-52. doi: 10.1002/jms.1369. J Mass Spectrom. 2008. PMID: 18286663

9

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.

Widmer N, Decosterd LA, Leyvraz S, Duchosal MA, Rosselet A, Debiec-Rychter M, Csajka C, Biollaz J, Buclin T. Widmer N, et al. Br J Cancer. 2008 May 20;98(10):1633-40. doi: 10.1038/sj.bjc.6604355. Epub 2008 May 6. Br J Cancer. 2008. PMID: 18475296 Free PMC article.

10

[Principles of therapeutic drug monitoring].

Widmer N, Csajka C, Werner D, Grouzmann E, Decosterd LA, Eap CB, Biollaz J, Buclin T. Widmer N, et al. Rev Med Suisse. 2008 Jul 16;4(165):1644-8. Rev Med Suisse. 2008. PMID: 18767290 Review. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

92 results

Search Page

Filters